• Je něco špatně v tomto záznamu ?

Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis: Predictors of Gamma Glutamyltransferase Normalization and Favorable Clinical Course

M. Deneau, E. Perito, A. Ricciuto, N. Gupta, BM. Kamath, S. Palle, B. Vitola, V. Smolka, F. Ferrari, AZ. Amir, T. Miloh, A. Papadopoulou, P. Mohan, C. Mack, KL. Kolho, R. Iorio, W. El-Matary, V. Venkat, A. Chan, L. Saubermann, PL. Valentino, U....

. 2019 ; 209 (-) : 92-96.e1. [pub] 20190314

Jazyk angličtina Země Spojené státy americké

Typ dokumentu srovnávací studie, časopisecké články, multicentrická studie, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20023911

Grantová podpora
UL1 RR025764 NCRR NIH HHS - United States
UL1 TR001863 NCATS NIH HHS - United States
P30 DK078392 NIDDK NIH HHS - United States
UL1 TR000105 NCATS NIH HHS - United States
UL1 TR002538 NCATS NIH HHS - United States
KL2 TR001065 NCATS NIH HHS - United States

OBJECTIVE: To investigate patient factors predictive of gamma glutamyltransferase (GGT) normalization following ursodeoxycholic acid (UDCA) therapy in children with primary sclerosing cholangitis. STUDY DESIGN: We retrospectively reviewed patient records at 46 centers. We included patients with a baseline serum GGT level ≥50 IU/L at diagnosis of primary sclerosing cholangitis who initiated UDCA therapy within 1 month and continued therapy for at least 1 year. We defined "normalization" as a GGT level <50 IU/L without experiencing portal hypertensive or dominant stricture events, liver transplantation, or death during the first year. RESULTS: We identified 263 patients, median age 12.1 years at diagnosis, treated with UDCA at a median dose of 15 mg/kg/d. Normalization occurred in 46%. Patients with normalization had a lower prevalence of Crohn's disease, lower total bilirubin level, lower aspartate aminotransferase to platelet ratio index, greater platelet count, and greater serum albumin level at diagnosis. The 5-year survival with native liver was 99% in those patients who achieved normalization vs 77% in those who did not. CONCLUSIONS: Less than one-half of the patients treated with UDCA have a complete GGT normalization in the first year after diagnosis, but this subset of patients has a favorable 5-year outcome. Normalization is less likely in patients with a Crohn's disease phenotype or a laboratory profile suggestive of more advanced hepatobiliary fibrosis. Patients who do not achieve normalization could reasonably stop UDCA, as they are likely not receiving clinical benefit. Alternative treatments with improved efficacy are needed, particularly for patients with already-advanced disease.

1st Pediatric Clinic University of Athens Athens Greece

Department of Gastroenterology Hepatology and Nutrition Children's National Medical Center Washington DC

Department of Pediatrics and Child Health University of Manitoba Winnipeg Manitoba Canada

Department of Pediatrics and Pediatric Neuropsychiatry Sapienza University of Rome Rome Italy

Department of Pediatrics Cincinnati Children's Hospital Medical Center Cincinnati OH

Department of Pediatrics Emory University School of Medicine Atlanta GA

Department of Pediatrics Harvard University Boston MA

Department of Pediatrics Medical College of Wisconsin Milwaukee WI

Department of Pediatrics Oklahoma University Oklahoma City OK

Department of Pediatrics Palacky University Olomouc Czech Republic

Department of Pediatrics Texas Children's Hospital Houston TX

Department of Pediatrics The Children's Hospital of Philadelphia Philadelphia PA

Department of Pediatrics The Hospital for Sick Children University of Toronto Toronto Ontario Canada

Department of Pediatrics University of California San Francisco San Francisco CA

Department of Pediatrics University of Colorado School of Medicine Aurora CO

Department of Pediatrics University of Helsinki Helsinki Finland

Department of Pediatrics University of Naples Federico 2 Naples Italy

Department of Pediatrics University of Pittsburgh Medical Center Pittsburgh PA

Department of Pediatrics University of Rochester Medical Center Rochester NY

Department of Pediatrics University of Utah Salt Lake City UT

Department of Pediatrics Yale University School of Medicine New Haven CT

Division of Gastroenterology Liver and Nutrition The Dana Dwek Children's Hospital Tel Aviv University Tel Aviv Israel

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023911
003      
CZ-PrNML
005      
20201214131652.0
007      
ta
008      
201125s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jpeds.2019.01.039 $2 doi
035    __
$a (PubMed)30878206
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Deneau, Mark $u Department of Pediatrics, University of Utah, Salt Lake City, UT. Electronic address: mark.deneau@hsc.utah.edu.
245    10
$a Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis: Predictors of Gamma Glutamyltransferase Normalization and Favorable Clinical Course / $c M. Deneau, E. Perito, A. Ricciuto, N. Gupta, BM. Kamath, S. Palle, B. Vitola, V. Smolka, F. Ferrari, AZ. Amir, T. Miloh, A. Papadopoulou, P. Mohan, C. Mack, KL. Kolho, R. Iorio, W. El-Matary, V. Venkat, A. Chan, L. Saubermann, PL. Valentino, U. Shah, A. Miethke, H. Lin, MK. Jensen,
520    9_
$a OBJECTIVE: To investigate patient factors predictive of gamma glutamyltransferase (GGT) normalization following ursodeoxycholic acid (UDCA) therapy in children with primary sclerosing cholangitis. STUDY DESIGN: We retrospectively reviewed patient records at 46 centers. We included patients with a baseline serum GGT level ≥50 IU/L at diagnosis of primary sclerosing cholangitis who initiated UDCA therapy within 1 month and continued therapy for at least 1 year. We defined "normalization" as a GGT level <50 IU/L without experiencing portal hypertensive or dominant stricture events, liver transplantation, or death during the first year. RESULTS: We identified 263 patients, median age 12.1 years at diagnosis, treated with UDCA at a median dose of 15 mg/kg/d. Normalization occurred in 46%. Patients with normalization had a lower prevalence of Crohn's disease, lower total bilirubin level, lower aspartate aminotransferase to platelet ratio index, greater platelet count, and greater serum albumin level at diagnosis. The 5-year survival with native liver was 99% in those patients who achieved normalization vs 77% in those who did not. CONCLUSIONS: Less than one-half of the patients treated with UDCA have a complete GGT normalization in the first year after diagnosis, but this subset of patients has a favorable 5-year outcome. Normalization is less likely in patients with a Crohn's disease phenotype or a laboratory profile suggestive of more advanced hepatobiliary fibrosis. Patients who do not achieve normalization could reasonably stop UDCA, as they are likely not receiving clinical benefit. Alternative treatments with improved efficacy are needed, particularly for patients with already-advanced disease.
650    _2
$a mladiství $7 D000293
650    _2
$a analýza rozptylu $7 D000704
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a dítě $7 D002648
650    _2
$a sklerozující cholangitida $x krev $x farmakoterapie $7 D015209
650    _2
$a kohortové studie $7 D015331
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a jaterní testy $7 D008111
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a časové faktory $7 D013997
650    _2
$a neúspěšná terapie $7 D017211
650    _2
$a výsledek terapie $7 D016896
650    _2
$a kyselina ursodeoxycholová $x terapeutické užití $7 D014580
650    _2
$a gama-glutamyltransferasa $x krev $7 D005723
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Perito, Emily $u Department of Pediatrics, University of California San Francisco, San Francisco, CA.
700    1_
$a Ricciuto, Amanda $u Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
700    1_
$a Gupta, Nitika $u Department of Pediatrics, Emory University School of Medicine, Atlanta, GA.
700    1_
$a Kamath, Binita M $u Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
700    1_
$a Palle, Sirish $u Department of Pediatrics, Oklahoma University, Oklahoma City, OK.
700    1_
$a Vitola, Bernadette $u Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI.
700    1_
$a Smolka, Vratislav $u Department of Pediatrics, Palacky University, Olomouc, Czech Republic.
700    1_
$a Ferrari, Federica $u Department of Pediatrics and Pediatric Neuropsychiatry, Sapienza University of Rome, Rome, Italy.
700    1_
$a Amir, Achiya Z $u Division of Gastroenterology, Liver and Nutrition, The Dana-Dwek Children's Hospital, Tel-Aviv University, Tel Aviv, Israel.
700    1_
$a Miloh, Tamir $u Department of Pediatrics, Texas Children's Hospital, Houston, TX.
700    1_
$a Papadopoulou, Alexandra $u First Pediatric Clinic, University of Athens, Athens, Greece.
700    1_
$a Mohan, Parvathi $u Department of Gastroenterology, Hepatology, and Nutrition, Children's National Medical Center, Washington, DC.
700    1_
$a Mack, Cara $u Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO.
700    1_
$a Kolho, Kaija-Leena $u Department of Pediatrics, University of Helsinki, Helsinki, Finland.
700    1_
$a Iorio, Raffaele $u Department of Pediatrics, University of Naples Federico II, Naples, Italy.
700    1_
$a El-Matary, Wael $u Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada.
700    1_
$a Venkat, Veena $u Department of Pediatrics, University of Pittsburgh Medical Center, Pittsburgh, PA.
700    1_
$a Chan, Albert $u Department of Pediatrics, University of Rochester Medical Center, Rochester, NY.
700    1_
$a Saubermann, Lawrence $u Department of Pediatrics, University of Rochester Medical Center, Rochester, NY.
700    1_
$a Valentino, Pamela L $u Department of Pediatrics, Yale University School of Medicine, New Haven, CT.
700    1_
$a Shah, Uzma $u Department of Pediatrics, Harvard University, Boston, MA.
700    1_
$a Miethke, Alexander $u Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
700    1_
$a Lin, Henry $u Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA.
700    1_
$a Jensen, M K $u Department of Pediatrics, University of Utah, Salt Lake City, UT.
773    0_
$w MED00002885 $t The Journal of pediatrics $x 1097-6833 $g Roč. 209, č. - (2019), s. 92-96.e1
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30878206 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214131650 $b ABA008
999    __
$a ok $b bmc $g 1596230 $s 1114587
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 209 $c - $d 92-96.e1 $e 20190314 $i 1097-6833 $m The Journal of pediatrics $n J Pediatr $x MED00002885
GRA    __
$a UL1 RR025764 $p NCRR NIH HHS $2 United States
GRA    __
$a UL1 TR001863 $p NCATS NIH HHS $2 United States
GRA    __
$a P30 DK078392 $p NIDDK NIH HHS $2 United States
GRA    __
$a UL1 TR000105 $p NCATS NIH HHS $2 United States
GRA    __
$a UL1 TR002538 $p NCATS NIH HHS $2 United States
GRA    __
$a KL2 TR001065 $p NCATS NIH HHS $2 United States
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...